Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
A phase 2 trial of Lutetium-177 vipivotide tetraxetan in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function is a phase 2 interventional study registered as NCT06004661 by Novartis Pharmaceuticals, with 23 participants enrolled, started 2024-04-04 and due to reach its primary completion in 2026-12-14. Interventions recorded: AAA617, 68Ga-PSMA-11. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAn Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Shares Lutetium-177 vipivotide tetraxetan, Novartis, Prostate cancer.
- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Shares Novartis, Prostate cancer.
- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Novartis, Prostate cancer.
- TrialA Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Shares Novartis, Prostate cancer.
- TrialOpen-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Shares Novartis, Prostate cancer.
- TrialStudy Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Shares Novartis, Prostate cancer.
- TrialStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Shares Novartis, Prostate cancer.
- TrialONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC